Publishers Alliance: CD151—A Striking Marker for Cancer Therapy
View web version
Drug Showcase
LENVIMA (lenvatinib)
For thyroid cancer.
Publishers Alliance
CD151—A Striking Marker for Cancer Therapy
By Seema Kumari, Gayatri Devi V., Anil Badana, Venkata Ramesh Dasari, and Rama Rao Malla
Feature
Multigene Cancer-Susceptibility Tests Require New Approaches to Patient Counseling
By

For more on the latest research and developments in oncology, visit our News section.

Latest News
Vismodegib Safe, Effective in Twelve-Month Study Update
Dovitinib Shows Activity in Advanced Endometrial Cancer
Chromosomal Instability Associated with Improved Outcomes in Breast Cancer

Want to receive emails specific to your profession and specialty? Click here to complete your profile.





Subscribe
If you were sent this by a colleague and wish to subscribe to Weekly highlights, please click here.

Unsubscribe
To unsubscribe from the Weekly Highlights click here.
To manage your entire Cancer Therapy Advisor profile login to your account.

You are subscribed as: %%EMAIL%%

To contact Haymarket Media for general questions or unsubscribe problems, please reply to this email.

All Cancer Therapy Advisor newsletters are sent from the domain "email.cancertherapyadvisor.com". When configuring e-mail or spam filter rules, please use this domain name.

© 2015 Haymarket Media Inc
114 West 26th St 4th floor
New York, NY 10001